Navigation Links
On track with the FDA -- But what about your coverage and reimbursement strategy?

Food and Drug Administration (FDA) approval or authorization is critical to any new medical technology or treatment's success. But coverage and reimbursement issues can be just as determinative.

"Coverage" is whether there will be payment by an insurer for the product. "Reimbursement" is how much payment there will be if there is coverage.

Unlike ......

Full article >>> edicare has enormous influence over other health plans because once Medicare agrees to pay for a new treatment, other insurers often follow suit.

Roles of the FDA and CMS

Medicare includes several major programs with different rules and administrative systems. All are managed by the Centers for Medicare and Medicaid (CMS). CMS, like the FDA, is an agency within the U.S. D......

Full article >>> uctures pay too low.

In making coverage decisions, CMS considers the following issues:

Does the product have FDA marketing approval or authorization (required except for certain investigational medical devices)?

Is it appropriate for the Medicare population?

Has it been proven medically necessary for the relevant disease or condition?

Does it improv......

Full article >>> ent decisions, such as studies that have both clinical and pharmacoeconomic endpoints (i.e., comparisons to existing technologies or treatments)

Early planning is essential to help ensure that the product will be covered and reimbursed appropriately.

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... 2017  BioGenex, a global leader in molecular ... novel system for quantitative immunohistochemistry (IHC). The system ... Rochester (NY, USA) and Konica-Minolta Inc. ( ... able to accurately quantify the expression of an ... factor receptor-2) in clinical samples. Quantitative IHC is ...
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, ... data on its oral peptide drug candidates, PTG-100 ... of the European Crohn,s and Colitis Organization (ECCO).  ... Barcelona, Spain from February 15 ... detail preclinical data on Protagonist drug candidates PTG-100 ...
(Date:2/16/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing ... treatment for triple negative breast cancer (TNBC), announced today their ... program. The YEi Start in ... entrepreneurs grow their business in France ... selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
Breaking Biology Technology:
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
Breaking Biology News(10 mins):